Trials / Unknown
UnknownNCT04309084
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting.
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 29 (estimated)
- Sponsor
- Celularity Incorporated · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will find the maximum tolerated dose (MTD) of CYNK-001 which contain NK cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given post Autologous Stem Cell Transplant (ASCT). The safety of this treatment will be evaluated, and researchers will want to learn if NK cells will help in treating Multiple Myeloma.
Conditions
- Multiple Myeloma
- Neoplasm, Plasma Cell
- Neoplasms by Histologic Type
- Neoplasms
- Hemostatic Disorder
- Vascular Diseases
- Cardiovascular Diseases
- Paraproteinemias
- Blood Protein Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Immune System Diseases
- Antineoplastic Agents
- Analgesics, Non-Narcotic
- Analgesics
- Sensory System Agents
- Peripheral Nervous System Agents
- Physiological Effects of Drugs
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CYNK-001 | CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells. |
Timeline
- Start date
- 2020-05-12
- Primary completion
- 2023-01-31
- Completion
- 2023-04-30
- First posted
- 2020-03-16
- Last updated
- 2023-02-16
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04309084. Inclusion in this directory is not an endorsement.